AI meets egg freezing
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Natalie Peeples/Axios
Sunfish — an AI-powered fertility platform — is introducing an egg-freezing program that uses predictive models to estimate the cost of reaching a target number of eggs.
Why it matters: Fertility treatments are a significant contributor to debt for many families in the U.S., but unlike mortgages, student debt or car payments, the treatments usually give people little transparency into what the final bill will be.
Driving the news: Sunfish's new egg-freezing program, launching Thursday, analyzes a patient's biodata to predict how many mature eggs she can expect to bank.
- The company will cover a second cycle at no cost if the target isn't met.
Catch up quick: Sunfish's program uses several million data points from fertility cycles to predict individual outcomes from IVF — and already "guarantees the cost of treatment to achieve the desired outcome," which usually means going home with a baby.
- Sunfish says its patients currently have a 70.8% success rate achieving pregnancy, versus a 54.3% national average.
By the numbers: "The typical IVF cycle costs about $25,000, but it takes most people two or three rounds of IVF," Angela Rastegar, Sunfish CEO, tells Axios.
- That can push IVF costs above $60,000.
- Medications, donor eggs, donor sperm and genetic testing all raise the costs.
- For many U.S. households, fertility treatment now constitutes the third or fourth largest expense, alongside mortgages, auto loans and student loans.
Between the lines: Most consumer AI for parents — chatbot tutors, AI toys and digital companions for toddlers — are impractical and potentially problematic.
- Sunfish proposes the opposite: a narrow, data-heavy platform where AI crunches millions of medical outcomes to predict its clients' success.
Yes, but: Most historical fertility data skews toward white people and the affluent — the same demographics that have had access to treatment.
- Rastegar says expanding access to care is one of the most important ways to build better, more representative data over time.
What we're watching: AI-driven health tools are drawing increased scrutiny from regulators.
- Sunfish positions its product as financial planning, not medical advice, but that distinction may be tested.
